到2031年，制药和生物技术市场中的可穿戴设备价值将达到99.7亿美元 MarketsandMarkets™-动脉网

Wearables in Pharma & Biotech Market worth $9.97 billion by 2031 | MarketsandMarkets™

PR Newswire 等信源发布 2026-04-02 22:31



可切换为仅中文







DELRAY BEACH, Fla.

佛罗里达州德尔雷海滩

，

April 2, 2026

2026年4月2日

/PRNewswire/ -- According to MarketsandMarkets™, the

/PRNewswire/ -- 根据MarketsandMarkets™的数据，

Wearables in Pharma & Biotech Market

制药与生物技术市场中的可穿戴设备

is projected to grow from about USD 3.98 billion in 2026 to USD 9.97 billion by 2031, at a CAGR of 20.2%.

预计到2031年，将从2026年的约39.8亿美元增长到99.7亿美元，年均复合增长率为20.2%。

Browse 531 market data Tables and 54 Figures spread through 457 Pages and in-depth TOC on 'Wearables in Pharma & Biotech Market- Global Forecast to 2031'

浏览包含531个市场数据表和54幅图表的457页，并深入了解《制药与生物技术领域的可穿戴设备市场-2031年全球预测》的详细目录。

Wearables in Pharma & Biotech Market Size & Forecast:

制药和生物技术市场中的可穿戴设备市场规模与预测：

Market Size Available for Years:

市场规模按年份提供：

2025–2031

2026 Market Size:

2026年市场规模：

USD 3.98 billion

39.8亿美元

2031 Projected Market Size:

2031年预计市场规模：

USD 9.97 billion

99.7亿美元

CAGR (2026–2031):

复合年均增长率（2026-2031）：

20.2%

Wearables in Pharma & Biotech Market Trends & Insights:

制药与生物技术市场中的可穿戴设备趋势与洞察：

In 2025, the continuous glucose monitor (CGM) segment accounted for 31.3% of the wearables in pharma & biotech market.

2025年，连续血糖监测仪（CGM）细分市场占制药和生物技术可穿戴设备市场的31.3%。

Pharmaceutical & biotech companies accounted for the largest share (53.5%) of the wearables in pharma & biotech market in 2025.

2025年，制药和生物技术公司占可穿戴设备在制药和生物技术市场中的最大份额（53.5%）。

North America accounted for the largest share (42.3%) of the global wearables in pharma & biotech market in 2025.

2025年，北美在全球制药和生物技术可穿戴设备市场中占据了最大份额（42.3%）。

Download PDF Brochure @

下载PDF手册 @

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=99537956

The market is gaining traction as the healthcare industry, governments, and pharma companies are adopting this technology to deliver better patient outcomes and successful clinical trials. The rise of

市场正在获得吸引力，因为医疗保健行业、政府和制药公司正在采用这种技术来提供更好的患者结果和成功的临床试验。随着...的崛起

decentralized

去中心化

and hybrid trials, which have been endorsed by the FDA in the US, is contributing to the growing use of wearables in the clinical research industry. This technology enhances the efficiency of conducting clinical trials and engaging patients. According to a research article published by PLOS Digital Health, 85% of studies utilizing wearables focus on monitoring patients with chronic diseases, with neurodegenerative diseases being the most prevalent.

并且美国FDA认可的混合试验，正在推动可穿戴设备在临床研究行业中的应用增长。这项技术提高了进行临床试验和患者参与的效率。根据PLOS数字健康杂志发表的一篇研究文章，85%使用可穿戴设备的研究集中在监测慢性病患者，其中神经退行性疾病是最常见的。

Additionally, 15% of studies are aimed at diagnosing diseases, primarily focusing on cardiovascular conditions. Notably, watches and bracelets represent 63% of the wearables employed in these studies. Even though only 8% of the studies were randomized trials, 67% showed clinical impact. However, according to the evidence provided by BMJ, the wearables used in clinical trials help in solving the challenges in this industry, and there are other aspects that need to be improved..

此外，15%的研究旨在诊断疾病，主要集中在心血管疾病上。值得注意的是，手表和手环占这些研究中使用的可穿戴设备的63%。尽管只有8%的研究是随机试验，但67%的研究显示出临床影响。然而，根据BMJ提供的证据，临床试验中使用的可穿戴设备有助于解决该行业的挑战，还有其他方面需要改进。

By therapeutic area, diabetes segment to register fastest growth during forecast period.

按治疗领域，糖尿病领域在预测期内将实现最快增长。

The diabetes segment is anticipated to show the highest growth rate in the wearables in pharma & biotech market during the forecast period. This is mainly because of the high rate of growth in the global diabetes population and the need for constant monitoring. According to the International Diabetes Federation (IDF) update of 2024, there are 589 million adults worldwide with diabetes mellitus.

预计在预测期内，糖尿病领域将展现出可穿戴设备在制药和生物技术市场中的最高增长率。这主要是由于全球糖尿病患者人数的快速增长以及对持续监测的需求。根据国际糖尿病联合会（IDF）2024年的更新数据，全球有5.89亿成年人患有糖尿病。

The numbers are projected to rise to over 850 million adults worldwide by 2050. This clearly indicates that there is a high rate of growth in the global population with diabetes. In the US, there are over 38 million people with diabetes, and nearly 1 in 3 adults has prediabetes. This clearly indicates that there is a high population that needs to be monitored.

到2050年，全球数字预计将增长至超过8.5亿成年人。这清楚地表明，全球糖尿病患者人口正在高速增长。在美国，有超过3800万糖尿病患者，几乎每3个成年人中就有1人处于糖尿病前期。这显然表明，有很大一部分人口需要被监测。

The global health expenditure on diabetes exceeded USD 1 trillion in 2023..

2023年，全球糖尿病医疗支出超过1万亿美元。

Request Sample Pages @

请求样本页面 @

https://www.marketsandmarkets.com/requestsampleNew.asp?id=99537956

By application, clinical trials segment held largest market share in 2025.

按应用划分，临床试验部分在2025年占据了最大的市场份额。

The clinical trials segment accounted for the largest share of the wearables in pharma & biotech industry in 2025. This is due to the increased need for efficient, patient-centric, and high-data-content study designs. According to the US Food and Drug Administration, there is increased focus on digital health technologies, such as wearables, in supporting .

2025年，临床试验部分在制药和生物技术行业的可穿戴设备领域占据了最大份额。这是由于对高效、以患者为中心且数据量大的研究设计的需求增加。根据美国食品药品监督管理局的信息，人们越来越关注支持数字健康技术，如可穿戴设备。

decentralized

去中心化

clinical trials. In 2023, the Tufts Center for the Study of Drug Development found that the average cost of developing a new drug is above USD 2.6 billion. This is encouraging pharma companies to use wearable-enabled monitoring in order to decrease the cost of clinical trials. According to Nature Medicine publications, there is an increased chance of collecting data as often as required by using wearable devices in comparison to conventional site-based methods of collecting endpoint data.

临床试验。2023年，塔夫茨药物开发研究中心发现，开发一种新药的平均成本超过26亿美元。这促使制药公司采用可穿戴设备监测来降低临床试验的成本。根据《自然医学》的出版物，与传统的基于站点的终点数据收集方法相比，使用可穿戴设备能够更频繁地按需收集数据。

All these factors are resulting in the dominance of the clinical trials segment in the wearables in pharma & biotech industry..

所有这些因素都导致了可穿戴设备在制药和生物技术行业的临床试验领域的主导地位。

North America accounted for largest market share in 2025.

北美在2025年占据了最大的市场份额。

North America accounted for the largest share of the global wearables in pharma & biotech market in 2025, given its high rate of adoption of connected health technologies and high integration of patient-generated data. According to PubMed Central research on wearables and health data, 44.5% of 23,974 respondents used wearables, and this rate was higher among younger people and people from urban and high-income areas.

北美在2025年占据了全球制药与生物技术领域可穿戴设备市场的最大份额，这得益于其对互联健康技术的高采纳率以及患者生成数据的高度整合。根据PubMed Central关于可穿戴设备与健康数据的研究，44.5%的23,974名受访者使用了可穿戴设备，且这一比例在年轻人和来自城市及高收入地区的人群中更高。

This suggests that there is a high consumer base that is generating continuous real-world health data for pharma and biotech use. North America is also benefiting from its high rate of innovation in wearables and other pharma and biotech technologies. For instance, there is significant funding and research support from institutions such as the National Institutes of Health and the National Science Foundation to support biosensors and other wearables and digital health technologies.

这表明存在一个庞大的消费者群体，他们正在为制药和生物技术用途生成持续的真实世界健康数据。北美也受益于其在可穿戴设备及其他制药和生物技术领域的高创新率。例如，美国国立卫生研究院和国家科学基金会等机构提供了大量资金和研究支持，以推动生物传感器、其他可穿戴设备及数字健康技术的发展。

Furthermore, there is reimbursement support for remote patient monitoring from the Centers for Medicare & Medicaid Services, which is further boosting the use of wearables and other integrated healthcare technologies in the region..

此外，美国医疗保险和医疗补助服务中心对远程患者监测提供报销支持，这进一步推动了该地区可穿戴设备和其他集成医疗技术的使用。

Inquire Before Buying @

购买前请咨询 @

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=99537956

Top Companies in Wearables in Pharma & Biotech Market:

制药和生物技术市场可穿戴设备领域的顶级公司：

The

Top Companies in Wearables in Pharma & Biotech Market

制药和生物技术市场中可穿戴设备的顶级公司

include BD (US), Abbott (US), Masimo (US), Apple Inc. (US), DexCom, Inc. (US), Medtronic (Ireland), iRhythm Technologies, Inc. (US), BioIntelliSense, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Koninklijke Philips N.V. (Netherlands), GE HealthCare (US), BioBeat Technologies Ltd. (Israel), Empatica Inc.

包括BD（美国）、Abbott（美国）、Masimo（美国）、苹果公司（美国）、DexCom, Inc.（美国）、Medtronic（爱尔兰）、iRhythm Technologies, Inc.（美国）、BioIntelliSense, Inc.（美国）、F. Hoffmann-La Roche Ltd（瑞士）、Koninklijke Philips N.V.（荷兰）、GE HealthCare（美国）、BioBeat Technologies Ltd.（以色列）、Empatica Inc.

(US), VitalConnect, Inc. (US), Ametris LLC (US), AliveCor, Inc. (US), Boston Scientific Corporation (US), Withings S.A. (France), VivaLNK, Inc. (US), and MediBioSense Ltd. (UK)..

（美国），VitalConnect公司（美国），Ametris有限责任公司（美国），AliveCor公司（美国），波士顿科学公司（美国），Withings股份有限公司（法国），VivaLNK公司（美国），MediBioSense有限公司（英国）。

Browse Adjacent Markets

浏览相邻市场

：

Healthcare IT Market Research

医疗保健IT市场研究

Reports & Consulting

报告与咨询

Related Reports:

相关报告：

Wearable Healthcare Devices Market

可穿戴医疗设备市场

- Global Forecast to 2030

- 全球预测至2030年

Medical Device Connectivity Market

医疗器械连接市场

- Global Forecast to 2028

- 全球预测至2028年

Clinical Trial Services Market

临床试验服务市场

- Global Forecast to 2030

- 全球预测至2030年

Home Healthcare Market

家庭医疗市场

- Global Forecast to 2030

- 全球预测至2030年

Diabetes Care Devices Market

糖尿病护理设备市场

- Global Forecast to 2030

- 全球预测至2030年

About MarketsandMarkets™

关于MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

根据福布斯最近的报告，MarketsandMarkets™ 被评为美国最佳管理咨询公司之一。

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe..

MarketsandMarkets™ 是一家在增长咨询和项目管理领域的蓝海替代方案，利用人机协作的模式，为 B2B 领域的进步型组织推动超常增长。凭借对新兴技术的最广泛视角，我们擅长与全球客户共同创造超常增长。

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

如今，80%的《财富》2000强企业依赖市场与市场公司，每个行业的前100家企业中有90家信任我们帮助他们加速收入增长。我们拥有超过13,000家全球客户，助力企业在颠覆性生态系统中蓬勃发展。

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing..

B2B经济正在见证新的收入流的出现，这些收入流在本十年内将取代现有的收入流，规模达25万亿美元。我们与客户合作开展增长计划，通过我们的服务项目帮助他们实现这一25万亿美元的机会——服务项目包括：TAM扩展、上市（GTM）战略到执行、市场份额增长、账户支持以及思想领导力营销。

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts..

基于“GIVE Growth”原则，我们与多家《福布斯》全球2000强B2B企业合作，助其未来就绪。我们的洞察与策略由行业专家、尖端人工智能以及我们的市场情报云平台KnowledgeStore™驱动，该平台整合研究并提供生态系统范围内的收入变化可见性。

MarketsandMarkets™

莫克特斯马克™

SalesPlay

销售策略

is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

是一个由人工智能驱动的收入智能副驾，旨在帮助收入团队优先处理正确的账户、及早识别关键变化并在需求之前发现机会，从而自然构建渠道并更加一致地达成交易。

To find out more, visit

要了解更多信息，请访问

www.MarketsandMarkets™.com

or follow us on

或关注我们

Twitter

，

领英

and

和

Facebook